Key Drivers
- Strong Cash Flow
- Rising Liquidity Risk
- High Intangibles
AIAI Summary
Haleon remains a high-cash-flow consumer-health franchise, but investors should treat it as a balance-sheet execution story until management clearly addresses the 2027 debt maturity and shrinking liquidity; upside depends on orderly refinancing alongside sustained brand investment and organic growth.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Rising Liquidity Risk
- •High Intangibles
HLN delivers strong margins and cash flow, but elevated leverage, worsening liquidity, and heavy intangible exposure warrant caution despite reasonable—not cheap—valuation.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold momentum
- •Support test
HLN remains bearish over the last month below its moving average, with oversold RSI (~22) allowing for a rebound only if it holds $9.19–$9.21 and reclaims $9.39.
Selling accelerated after the $10.18 high, driving a roughly 6% decline
Sentiment & News
Key News Insights:
- •Margin strength
- •Retail expansion
- •GLP-1 demand
Haleon's margin outperformance, improved retail visibility, and GLP-1-related demand support growth, though investment and valuation remain key watchpoints.
The news is moderately positive for Haleon, reinforcing growth potential while highlighting execution and investment risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings